Cocrystal Pharma logo

Cocrystal PharmaNASDAQ: COCP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 February 2012

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$18.41 M
-80%vs. 3y high
24%vs. sector
-vs. 3y high
-vs. sector
-25%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 30 Oct 2024 20:00:01 GMT
$1.81-$0.08(-4.11%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

COCP Latest News

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
globenewswire.com19 August 2024 Sentiment: POSITIVE

BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .'s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
accesswire.com15 August 2024 Sentiment: POSITIVE

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.

Penny Stocks To Buy Now? 4 Under $3 To Watch This Week
PennyStocks10 April 2023 Sentiment: NEUTRAL

Penny stocks to watch this week under $3. The post Penny Stocks To Buy Now?

What type of business is Cocrystal Pharma?

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

What sector is Cocrystal Pharma in?

Cocrystal Pharma is in the Healthcare sector

What industry is Cocrystal Pharma in?

Cocrystal Pharma is in the Biotechnology industry

What country is Cocrystal Pharma from?

Cocrystal Pharma is headquartered in United States

When did Cocrystal Pharma go public?

Cocrystal Pharma initial public offering (IPO) was on 22 February 2012

What is Cocrystal Pharma website?

https://www.cocrystalpharma.com

Is Cocrystal Pharma in the S&P 500?

No, Cocrystal Pharma is not included in the S&P 500 index

Is Cocrystal Pharma in the NASDAQ 100?

No, Cocrystal Pharma is not included in the NASDAQ 100 index

Is Cocrystal Pharma in the Dow Jones?

No, Cocrystal Pharma is not included in the Dow Jones index

When was Cocrystal Pharma the previous earnings report?

No data

When does Cocrystal Pharma earnings report?

The next expected earnings date for Cocrystal Pharma is 13 November 2024